摘要
目的研究人肿瘤坏死因子相关凋亡诱导配体受体在卵巢上皮癌中的表达。方法采用免疫组化方法,检测TRAIL 4个受体DR4、DR5、DcR1、DcR2在6例正常卵巢组织、12例良性卵巢上皮性肿瘤及32例卵巢上皮癌中的表达。结果DR4、DR5、DcR1、DcR2表达阳性染色主要定位于肿瘤细胞胞浆或胞膜中;在正常卵巢组织中和卵巢良性肿瘤组织中4个受体均呈高表达,相互间差异无统计学意义;而在卵巢上皮癌组织中假受体DcR1、DcR2的表达率(44%、22%)显著低于在卵巢良性肿瘤组织(83%,100%)和正常卵巢组织(100%、83%)的表达率,差异有高度统计学意义(P<0.01);卵巢上皮癌中DR4、DR5、DcR1、DcR2的表达与临床期别、分化程度、组织类型无关(P>0.05)。结论在正常卵巢、良性卵巢上皮肿瘤及卵巢上皮癌中TRAIL 4个受体DR4、DR5、DcR1、DcR2均有表达,但在卵巢上皮性癌中假受体DcR1、DcR2的表达率明显减少,可能与卵巢癌的发生有关。
Objective To investigate the expression of TRAIL receptor in patients with epithelial ovarian carcinoma. Methods TRAIL receptor of DR4, DRS, DcR1 and DcR2 was detected using immunohistochemistry method in 6 normal ovarian tissues, 12 cases of benign tumor, and 32 cases of ovarian carcinoma, respectively. Results TRAIL receptor expression was revealed in neoplasitc mem- brane or cytoplasm. The TRAIL receptor of DR4, DR5, DcR1 and DcR2 expression was high in normal ovarian tissues and benign tumors, but there was no significant difference between them. The rate of decoy receptor DcR1, DcR2 expression （44 %, 22 % ） in ovarian carcinoma was lower than that in normal ovarian tissues （ 100 %, 83 % ） and benign tumors （83 %, 100 % ） （ P 〈 0.01 ）. The level of TRAIL receptor of DR4, DR5, DcR1 and DcR2 expression in ovarian carcinoma did not correlate with clinical stage and histological grade（P 〉 0.05）. Conclusions The TRAIL receptor of DR4, DtCS, DcR1 and DcR2 is all revealed txxsitive expression in normal ovarian tissues, benign tumors and ovarian carcinoma, while the rate of decoy receptor DcR1 and DcR2 expression in epithelium ovarian carcinoma is markedly decreased. It suggests that the low expression of TRAIL decoy receptor DcR1 and DcR2 may play a role in the ontogenesis of ovarian carcinoma.
出处
《苏州大学学报（医学版）》
CAS
北大核心
2007年第4期566-568,共3页
Suzhou University Journal of Medical Science
基金
苏州大学附属第一医院科研基金资助项目(H0307)
